PRDS NASDAQ
Pardes Biosciences, Inc.
1W: +0.0%
1M: +3.4%
3M: +14.3%
1Y: -31.9%
$2.18
Last traded 2023-09-08 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$201M
-27.1% ▼
Total Liabilities
$20M
+127.8% ▲
Shareholders Equity
$180M
-32.3% ▼
Cash & Investments
$197M
-26.6% ▼
Total Debt
$0
+0.0% ▲
Net Debt
-$59M
+77.9% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| — Assets — | |||
| Cash | $3M | $269M | $59M |
| Short-Term Investments | $0 | $0 | $138M |
| Cash & ST Investments | $3M | $269M | $197M |
| Net Receivables | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 |
| Other Current Assets | $194K | $7M | $3M |
| Total Current Assets | $4M | $275M | $200M |
| Property, Plant & Equip. | $0 | $0 | $0 |
| Goodwill & Intangibles | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 |
| Other Non-Current Assets | $0 | $0 | $219K |
| Total Non-Current Assets | $0 | $0 | $219K |
| Total Assets | $4M | $275M | $201M |
| — Liabilities — | |||
| Accounts Payable | $1M | $2M | $5M |
| Short-Term Debt | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 |
| Other Current Liabilities | $15M | $7M | $15M |
| Total Current Liabilities | $17M | $9M | $20M |
| Long-Term Debt | $0 | $0 | $0 |
| Other Non-Current Liab. | $0 | $0 | $0 |
| Total Non-Current Liabilities | $0 | $0 | $5M |
| Total Liabilities | $17M | $9M | $20M |
| — Equity — | |||
| Common Stock | $0 | $6K | $6K |
| Retained Earnings | -$13M | -$52M | -$148M |
| Accumulated OCI | $0 | $0 | -$24K |
| Total Stockholders Equity | -$13M | $266M | $180M |
| Total Liabilities & Equity | $4M | $275M | $201M |
| — Key Metrics — | |||
| Total Debt | $0 | $0 | $0 |
| Net Debt | -$3M | -$269M | -$59M |
| Total Investments | $0 | $0 | $138M |